Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands.
Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands.
复制标题
DOI：
10.1002/hed.25035
复制
发表时间：
2018-03
期刊：
影响因子：
--
通讯作者：
van Herpen CML
中科院分区：
文献类型：
--
作者：
Boon E;van Boxtel W;Buter J;Baatenburg de Jong RJ;van Es RJJ;Bel M;Fiets E;Oosting SF;Slingerland M;Hoeben A;Tesselaar MET;Jonker MA;Flucke UE;Nationwide Network and Registry of Histopathology and Cytopathology (PALGA) Group;van der Graaf WTA;van Herpen CML
涎腺导管癌是涎腺癌的一种侵袭性亚型，主要是雄激素受体阳性。关于雄激素剥夺疗法(ADT)的数据有限。对接受一线ADT治疗的晚期雄激素受体阳性涎腺导管癌患者的临床益处(即部分缓解[PR]和疾病稳定、无进展生存[PFS]和总生存[OS])进行了回顾性评估。将OS与接受最佳支持治疗的晚期涎腺导管癌患者进行比较。在接受ADT治疗的35名患者中，有34名是可评估的：6名患者有PR(18%)，11名患者有稳定的疾病(32%)，导致临床受益率为50%。接受ADT治疗的患者的中位PFS为4个月，临床受益的中位持续时间为11个月。接受最佳支持治疗的43名患者的中位OS为17个月，而接受最佳支持治疗的患者为5个月(P = .02)。考虑到ADT的疗效和临床益处，我们推荐ADT治疗晚期雄激素受体阳性的涎腺导管癌。©2017威利期刊，Inc.Head Neck，2017
Salivary duct carcinoma, an aggressive subtype of salivary gland cancer, is mostly androgen receptor‐positive. Only limited data are available on androgen deprivation therapy (ADT). Patients with advanced androgen receptor‐positive salivary duct carcinoma treated with first‐line ADT were retrospectively evaluated for clinical benefit (ie, partial response [PR] and stable disease, progression‐free survival [PFS] and overall survival [OS]). The OS was compared with patients with advanced salivary duct carcinoma who received best supportive care. Thirty‐four of 35 patients who were ADT‐treated were evaluable: 6 patients had a PR (18%) and 11 had stable disease (32%) leading to a clinical benefit ratio of 50%. The median PFS for the ADT‐treated patients was 4 months and the median duration of clinical benefit was 11 months. The median OS was 17 months versus 5 months in 43 patients receiving best supportive care (P = .02). We recommend ADT in advanced androgen receptor‐positive salivary duct carcinoma given its response and clinical benefit. © 2017 Wiley Periodicals, Inc. Head Neck, 2017
登录
查看更多内容
DOI：
10.1056/nejmoa1503747
发表时间：
2015-08-20
期刊：
The New England journal of medicine
影响因子：
--
作者：
Sweeney CJ;Chen YH;Carducci M;Liu G;Jarrard DF;Eisenberger M;Wong YN;Hahn N;Kohli M;Cooney MM;Dreicer R;Vogelzang NJ;Picus J;Shevrin D;Hussain M;Garcia JA;DiPaola RS
通讯作者：
DiPaola RS
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
恩扎拉胺：靶向转移性cast割前列腺癌中的雄激素信号通路。
影响因子：
4.5
作者：
Schalken J;Fitzpatrick JM
通讯作者：
Fitzpatrick JM
DOI：
10.1056/nejmoa1502309
发表时间：
2015-08-20
期刊：
The New England journal of medicine
影响因子：
--
作者：
Hyman DM;Puzanov I;Subbiah V;Faris JE;Chau I;Blay JY;Wolf J;Raje NS;Diamond EL;Hollebecque A;Gervais R;Elez-Fernandez ME;Italiano A;Hofheinz RD;Hidalgo M;Chan E;Schuler M;Lasserre SF;Makrutzki M;Sirzen F;Veronese ML;Tabernero J;Baselga J
通讯作者：
Baselga J
影响因子：
4.8
作者：
Locati, Laura D.;Perrone, Federica;Licitra, Lisa
通讯作者：
Licitra, Lisa